Perrigo (PRGO)

Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Perrigo Company plc (NYSE:PRGO ) Perrigo 2025 Investor Day February 28, 2025 8:00 AM ET Company Participants Brad Joseph - Vice President, Investor Relations Patrick Lockwood-Taylor - President and Ch...

PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.

This week sees 31 dividend increases, including three Dividend Kings: Genuine Parts, Commerce Bancshares, and Kimberly-Clark, showcasing impressive financial stability and growth. My investment strate...

While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compar...

Perrigo (PRGO) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.86 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qu...

PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.

Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.

Perrigo is a focused OTC consumer healthcare player, slimming down operations and enhancing margins under new management, with a 4.6% dividend yield. Despite short-term pressures from a weak cold-and-...